Additional file 5 of Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy
presentationposted on 20.11.2020, 15:06 authored by Razan Sheta, Magdalena Bachvarova, Marie Plante, Marie-Claude Renaud, Alexandra Sebastianelli, Jean Gregoire, Jamilet Miranda Navarro, Ricardo Bringas Perez, Jean-Yves Masson, Dimcho Bachvarov
Additional file 5. The effect of olaparib and niraparib on EMT in PARPis-resistant AsPCs. AsPCs were grown in monolayers for 48 h and then treated with either olaparib at a concentration of 50 μM for a period of 24 h, or niraparib at a concentration of 25 μM for a period of 24 h, as non-treated AsPCs were used as controls. Western blot protein expression analysis of the two EMT markers, (A) olaparib resistant and (B) niraparib resistant AsPCs. Actin was used as the loading control.